PolyPid Ownership

PYPD Stock  USD 4.71  0.13  2.84%   
PolyPid owns a total of 16.63 Million outstanding shares. 30% of PolyPid outstanding shares are owned by third-party entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
 
Shares in Circulation  
First Issued
2017-09-30
Previous Quarter
12.8 M
Current Value
20.1 M
Avarage Shares Outstanding
3.2 M
Quarterly Volatility
4.5 M
 
Covid
 
Interest Hikes
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PolyPid. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation.
For information on how to trade PolyPid Stock refer to our How to Trade PolyPid Stock guide.

PolyPid Stock Ownership Analysis

About 16.0% of the company outstanding shares are owned by corporate insiders. The book value of PolyPid was at this time reported as 0.92. The company recorded a loss per share of 2.81. PolyPid had not issued any dividends in recent years. The entity had 1:30 split on the 21st of September 2023. PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix platform to address unmet medical needs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. Polypid operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 75 people. To find out more about PolyPid contact the company at 972 7 4719 5700 or learn more at https://www.polypid.com.
Besides selling stocks to institutional investors, PolyPid also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different PolyPid's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align PolyPid's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

PolyPid Quarterly Liabilities And Stockholders Equity

26.84 Million

About 16.0% of PolyPid are currently held by insiders. Unlike PolyPid's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against PolyPid's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of PolyPid's insider trades

PolyPid Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as PolyPid is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading PolyPid backward and forwards among themselves. PolyPid's institutional investor refers to the entity that pools money to purchase PolyPid's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Northwestern Mutual Wealth Management Co2025-06-30
K
Advisor Group Holdings, Inc.2025-06-30
467
Sbi Securities Co Ltd2025-06-30
1.0
Td Waterhouse Canada Inc2025-03-31
0.0
Yelin Lapidot Holdings Management Ltd2025-06-30
0.0
Ubs Group Ag2025-03-31
0.0
Stonepine Capital Management Llc2025-06-30
0.0
Aigh Capital Management, Llc2025-06-30
1.2 M
Rosalind Advisors, Inc.2025-06-30
975.5 K
Dafna Capital Management Llc2025-06-30
207.9 K
J. Goldman & Co Lp2025-06-30
199.3 K
Note, although PolyPid's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

PolyPid Outstanding Bonds

PolyPid issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. PolyPid uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most PolyPid bonds can be classified according to their maturity, which is the date when PolyPid has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether PolyPid is a strong investment it is important to analyze PolyPid's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact PolyPid's future performance. For an informed investment choice regarding PolyPid Stock, refer to the following important reports:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PolyPid. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation.
For information on how to trade PolyPid Stock refer to our How to Trade PolyPid Stock guide.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Will Biotechnology sector continue expanding? Could PolyPid diversify its offerings? Factors like these will boost the valuation of PolyPid. Anticipated expansion of PolyPid directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every PolyPid data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(2.81)
Return On Assets
(0.88)
Return On Equity
(3.91)
The market value of PolyPid is measured differently than its book value, which is the value of PolyPid that is recorded on the company's balance sheet. Investors also form their own opinion of PolyPid's value that differs from its market value or its book value, called intrinsic value, which is PolyPid's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because PolyPid's market value can be influenced by many factors that don't directly affect PolyPid's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between PolyPid's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding PolyPid should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, PolyPid's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.